Management of sickle cell disease patients presenting to the emergency department with vaso-occlusive crisis: a retrospective study

Zainab Abdullah Al Hussaini; Raghad Al Kanhal; Futoon Al Ebrahaimi; Mohammed Al Shalhoub; Bader Al Asmari; Fatmah Othman

doi:10.18203/2320-6012.ijrms20233970

Authors

Zainab Abdullah Al Hussaini Department of Emergency Medicine, At King Abdulaziz Medical City, Riyadh, Saudi Arabia
Raghad Al Kanhal Department of Emergency Medicine, At King Abdulaziz Medical City, Riyadh, Saudi Arabia
Futoon Al Ebrahaimi Department of Emergency Medicine, At King Abdulaziz Medical City, Riyadh, Saudi Arabia
Mohammed Al Shalhoub Department of Emergency Medicine, At King Abdulaziz Medical City, Riyadh, Saudi Arabia
Bader Al Asmari Department of Emergency Medicine, At King Abdulaziz Medical City, Riyadh, Saudi Arabia
Fatmah Othman Department Epidemiology and Biostatistics, College of Public Health and Health Informatics, King Saud Bin Abdulaziz University for Health Science, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

DOI:

https://doi.org/10.18203/2320-6012.ijrms20233970

Keywords:

SCA, VOC, Better outcomes

Abstract

Background: Sickle cell anemia (SCA) is a hereditary disease of the hemoglobin, characterized by recurring vaso-occlusive crises (VOC) leading to severe pain. VOCs constitute the primary cause for emergency department (ED) visits among sicklers. Frequent VOC episodes are associated with greater mortality. This study aimed to evaluate pain treatment trends regarding admission, discharge, length of stay in the ED, and early ED revisits among SCA patients.

Methods: A cross-sectional study was conducted from January 2020 to January 2023 at the ED of King Abdulaziz medical city in Riyadh. SCA patients who presented with VOC episodes were included in this study. Demographic and clinical data of each patient were retrieved from the electronic medical file.

Results: Total of 144 patients were included in the analysis. Out of the total population, 34% were admitted to hospital. Compared to those patients who were not admitted, the number of VOC was more among patients who had been admitted. Around 34% had ED revisit within 30 days and those patients had higher frequency of VOC attacks compared to those who did not revisit the ED. Only 45% of the population received appropriate dosing, 30% received an insufficient dose, and 25% received over the appropriate dose. Receiving the correct dose of morphine reduced the likelihood of ED revisits within 30 days.

Conclusions: This study explores trends in VOC among sticklers, highlighting that adequate analgesia is associated with better outcomes. Addressing these variables may lead to improved care and better outcomes for SCA patients.

Metrics

Metrics Loading ...

References

Weatherall DJ. The inherited diseases of haemoglobin are an emerging global health burden. Blood. 2010;115(22):4331-6.

DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK et al. American Society of Hematology 2020 guidelines for sickle cell disease: Prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-88.

Robert D, Kyle CB. Pain management for sickle cell disease. Cochrane Library, John Wiley and Sons, Ltd. 2006.

Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull Worl Heal Org. 2008;86(6):480-87.

Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Ann Saudi Med. 2011;31(3):289-93.

Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014;124(26):3850-4004.

Ndefo UA, Maxwell AE, Nguyen H, Chiobi TL. Pharmacological management of sickle cell disease. P T Peer-reviewed J Formulary Management. 2008;33(4):238-43.

Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology. Am Society Hematol Education Program. 2005;58-65.

Glassberg JA, Tanabe P, Chow A, Harper K, Haywood C Jr, DeBaun MR et al. Emergency provider analgesic practices and attitudes toward patients with sickle cell disease. Ann Emergency Med. 2013;62(4):293-302.e10.

Labbé E, Herbert D, Haynes J. Physicians' attitude and practices in sickle cell disease pain management. J Palliative Care. 2005;21(4):246-51.

Lovett PB, Sule HP, Lopez BL. Sickle Cell Disease in the Emergency Department. Hematol/ Oncol Clin N Am. 2017;31(6):1061-79.

Puri Singh A, Haywood C Jr, Beach MC, Guidera M, Lanzkron S, Valenzuela-Araujo D et al. Improving Emergency Providers' Attitudes Toward Sickle Cell Patients in Pain. J Pain Symptom Management. 2016;51(3):628-32.e3.

Lazio MP, Costello HH, Courtney DM, Martinovich Z, Myers R, Zosel A et al. A comparison of analgesic management for emergency department patients with sickle cell disease and renal colic. Clin J Pain. 2010;26(3):199-205.

Solomon LR. Pain management in adults with sickle cell disease in a medical center emergency department. J National Med Asso. 2010;102(11):1025-32.

Tanabe P, Myers R, Zosel A, Brice J, Ansari AH, Evans J et al. Emergency department management of acute pain episodes in sickle cell disease. Academic Emergency Med. 2007;14(5):419-25.

Jacob SA, Mueller EL, Cochrane AR, Carroll AE, Bennett WE Jr. Variation in hospital admission of sickle cell patients from the emergency department using the Pediatric Health Information System. Pediatr Blood Cancer. 2020;67(6):e28067.

Lyon M, Sturgis L, Lottenberg R, Gibson ME, Eck J, Kutlar A et al. Outcomes of an Emergency Department Observation Unit-Based Pathway for the Treatment of Uncomplicated Vaso-occlusive Events in Sickle Cell Disease. Annals of emergency Med. 2020;76(3S):S12-20.

Givens M, Rutherford C, Joshi G, Delaney K. Impact of an emergency department pain management protocol on the pattern of visits by patients with sickle cell disease. J Emergency Med. 2007;32(3):239-43.

Ender KL, Krajewski JA, Babineau J, Tresgallo M, Schechter W, Saroyan JM et al. Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease. Pediatric blood & cancer. 2014;61(4):693-6.

Lyon M, Sturgis L, Lottenberg R, Gibson ME, Eck J, Kutlar A. Outcomes of an Emergency Department Observation Unit-Based Pathway for the Treatment of Uncomplicated Vaso-occlusive Events in Sickle Cell Disease. Ann Emergency Med. 2020;76(3S):S12-20.

Solomon LR. Pain management in adults with sickle cell disease in a medical centre emergency department. J National Med Asso. 2010;102(11):1025-32.

Glassberg J, Simon J, Patel N, Jeong JM, McNamee JJ, Yu G. Derivation and preliminary validation of a risk score to predict 30-day ED revisits for sickle cell pain. Am J Emergency Med. 2015;33(10):1396-401.

Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288-94.

Okorji LM, Muntz DS, Liem RI. Opioid prescription practices at discharge and 30-day returns in children with sickle cell disease and pain. Pediatr Blood Cancer. 2017;64(5):10.1002/pbc.26319.